Modular Medical Appoints David Bosshard to Lead its International Expansion for the Pivot Insulin Delivery System
Modular Medical (NASDAQ:MODD) appointed David Bosshard as Head of International Operations to accelerate global rollout of its next‑generation Pivot insulin delivery system. Bosshard brings two decades of experience launching tubeless patch pumps and previously helped grow Omnipod users to nearly 70,000 and launch YpsoPump across 20+ countries. Modular Medical is advancing Pivot through U.S. and CE Mark regulatory processes while building on its FDA‑cleared MODD1 pump and targeting the >$3 billion adult "almost‑pumpers" market. The Pivot system is not currently cleared for sale by the FDA. The company warned that regulatory, manufacturing, market acceptance, and other risks could affect outcomes.
Modular Medical (NASDAQ:MODD) ha nominato David Bosshard come Responsabile delle Operazioni Internazionali per accelerare la diffusione globale del suo sistema di somministrazione insulina di nuova generazione Pivot. Bosshard porta due decenni di esperienza nello lancio di pompe patch senza serbatoio e in passato ha contribuito a portare gli utenti Omnipod a quasi 70.000 e a lanciare YpsoPump in oltre 20 paesi. Modular Medical sta avanzando Pivot attraverso i processi regolatori statunitensi e di marcatura CE, sfruttando la pompa MODD1 approvata dalla FDA e mirando al mercato degli adulti “quasi-pompa” valutato oltre i 3 miliardi di dollari. Il sistema Pivot non è attualmente approvato per la vendita dalla FDA. L'azienda avverte che rischi regolatori, di produzione, di accettazione di mercato e altri rischi potrebbero influire sugli esiti.
Modular Medical (NASDAQ:MODD) designó a David Bosshard como Director de Operaciones Internacionales para acelerar la implementación global de su sistema de administración de insulina de próxima generación Pivot. Bosshard aporta dos décadas de experiencia en el lanzamiento de bombas patch sin pilas y, previamente, ayudó a que los usuarios de Omnipod alcanzaran casi 70,000 y a lanzar YpsoPump en más de 20 países. Modular Medical está avanzando Pivot a través de los procesos regulatorios de EE. UU. y la marca CE, mientras continúa con la bomba MODD1 con aprobación de la FDA y apunta al mercado de adultos de “casi-pompas” con un valor superior a los 3 mil millones de dólares. El sistema Pivot no está actualmente aprobado para la venta por la FDA. La empresa advirtió que riesgos regulatorios, de manufactura, aceptación del mercado y otros podrían afectar los resultados.
Modular Medical (NASDAQ:MODD) 는 차세대 Pivot 인슐린 전달 시스템의 글로벌 출시를 가속화하기 위해 David Bosshard를 국제 운영 책임자로 임명했습니다. Bosshard는 무관 패치 펌프를 출시한 20년 간의 경험을 갖고 있으며 이전에는 Omnipod 사용자를 거의 70,000명으로 성장시키고 YpsoPump를 20개국 이상에 출시하는 데 기여했습니다. Modular Medical은 Pivot 를 미국의 규제 및 CE 마크 규제 절차를 통해 추진하는 한편 FDA 승인 MODD1 펌프를 바탕으로 30억 달러를 상회하는 성인용 ‘거의 펌프’ 시장을 겨냥하고 있습니다. Pivot 시스템은 현재 FDA의 판매 승인을 받지 않았습니다. 회사는 규제, 제조, 시장 수용 및 기타 위험이 결과에 영향을 미칠 수 있다고 경고했습니다.
Modular Medical (NASDAQ:MODD) a nommé David Bosshard au poste de Responsable des Opérations Internationales afin d'accélérer le déploiement mondial de son système de délivrance d'insuline de nouvelle génération Pivot. Bosshard apporte deux décennies d'expérience dans le lancement de pompes patch sans réservoir et a aidé auparavant à faire passer le nombre d'utilisateurs Omnipod à près de 70 000 et à lancer YpsoPump dans plus de 20 pays. Modular Medical fait progresser Pivot à travers les processus réglementaires américains et la marque CE, tout en s'appuyant sur la pompe MODD1 approuvée par la FDA et en visant le marché des adultes “presque-pompes” évalué à plus de 3 milliards de dollars. Le système Pivot n'est pas actuellement approuvé pour la vente par la FDA. L'entreprise a averti que des risques réglementaires, de fabrication, d'acceptation du marché et d'autres risques pourraient affecter les résultats.
Modular Medical (NASDAQ:MODD) hat David Bosshard zum Leiter der Internationalen Operationen ernannt, um die globale Einführung seines nächsten Generation Pivot‑Insulinverteilungssystems zu beschleunigen. Bosshard bringt zwei Jahrzehnte Erfahrung mit dem Start tubeless Patch Pumps mit und hat zuvor geholfen, die Omnipod-Nutzer auf fast 70.000 zu bringen und YpsoPump in mehr als 20 Ländern einzuführen. Modular Medical treibt Pivot durch US‑Regulierungsprozesse und CE‑Marke voran, während es auf den FDA-geprüften MODD1‑Pumpe aufbaut und den 3‑Milliarden-Dollar‑Markt der erwachsenen „fast-Pumper“ anvisiert. Das Pivot‑System ist derzeit nicht von der FDA für den Verkauf freigegeben. Das Unternehmen warnte, dass regulatorische, Herstellungs-, Marktakzeptanz- und andere Risiken die Ergebnisse beeinflussen könnten.
Modular Medical (NASDAQ:MODD) عيّنت ديفيد بوشارد كـ رئيس العمليات الدولية لتعجيل التوسع العالمي لنظام توصيل الأنسولين من الجيل التالي Pivot. يجلب بوشارد خبرة تزيد عن عقدين في إطلاق مضخات التصحيح اللاسلكية، وساعد سابقاً في زيادة عدد مستخدمي Omnipod إلى ما يقرب من 70,000 وإطلاق YpsoPump في أكثر من 20 دولة. تقوم Modular Medical بتطوير Pivot من خلال العمليات التنظيمية في الولايات المتحدة ووفق علامة CE، مع البناء على مضخة MODD1 المعتمدة من FDA واستهداف سوق كبار السن من “القبلات-المضخات” التي تتجاوز قيمتها 3 مليارات دولار. النظام Pivot غير معتمد حالياً للبيع من قبل FDA. حذّرت الشركة من أن المخاطر التنظيمية والتصنيعية وقبول السوق وغيرها قد تؤثر على النتائج.
Modular Medical (NASDAQ:MODD) 任命 David Bosshard 为国际运营主管，以加速其下一代注射胰岛素递送系统 Pivot 在全球的推广。Bosshard 拥有二十年的无筒装置针贴泵（tubeless patch pumps）推出经验，曾帮助 Omnipod 用户增长到接近 70,000，并在 20 多个国家推出 YpsoPump。Modular Medical 正通过美国监管与 CE 标准流程推进 Pivot，同时在 FDA 批准的 MODD1 泵基础上，瞄准成人“几乎像泵”的市场，预计规模超过 30 亿美元。Pivot 系统当前未获 FDA 销售批准。公司警告称，监管、制造、市场接受度及其他风险可能影响结果。
- Bosshard led European Omnipod launch growing users to nearly 70,000
- Company advancing Pivot through U.S. and CE Mark regulatory processes
- Strategic focus on >$3 billion adult "almost‑pumpers" market
- Pivot insulin delivery system is not currently cleared for sale by the FDA
- Forward‑looking statements cite regulatory, manufacturing, and market acceptance risks
-Seasoned Executive with Proven Track Record in International Pump Launches to Accelerate Global Adoption of User Friendly, Affordable Patch Pumps
SAN DIEGO, CA, CA / ACCESS Newswire / October 6, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the
Bosshard's appointment comes at a pivotal time, as Modular Medical advances its next-generation Pivot insulin delivery system through the U.S. and CE Mark regulatory processes, building on the Company's U.S. Food and Drug Administration ("FDA") cleared MODD1 pump to enhance accessibility for underserved diabetes patients worldwide. His deep experience will accelerate the international rollout of the Pivot product, as the Company seeks to access international markets and unlock new revenue streams in the underserved, over
Key highlights of Bosshard's expertise and strategic impact:
Led the successful launch of Insulet's Omnipod patch pump in Europe at Ypsomed AG from 2010 to 2017, growing the user base to nearly 70,000, while overseeing business operations for 13 country affiliates, including product distribution and marketing support; and
As product area leader, spearheaded the 2017 launch of YpsoPump, driving CGM and AID integrations to deliver disruptive therapy outcomes; the system has since been distributed in over 20 countries across Europe, Australia and Canada.
"David's addition to our team is a game-changer for Modular Medical's international ambitions," said Jeb Besser, CEO of Modular Medical. "His success in scaling the Omnipod and launching YpsoPump with international users aligns perfectly with our mission to make affordable, intuitive patch pumps accessible worldwide. We're excited to harness his expertise in launching our Pivot product internationally, as we seek to access high-growth markets outside the U.S. and evaluate each for direct and indirect distribution opportunities."
Modular Medical is dedicated to revolutionizing insulin delivery with affordable, easy-to-use solutions for the millions of "almost-pumpers" who avoid traditional pumps due to complexity and cost. For more information on its insulin delivery system technology, visit www.modular-medical.com.
The Pivot insulin delivery system is not currently cleared for sale by the FDA.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's expected submissions of its Pivot product to regulatory agencies; the Company's intent to expand and offer its Pivot product for sale in markets outside the U.S.; the performance of the Company's products; expected deployments of the Company's pump products to persons with diabetes; the Company's ability to convert patients to use its pump products; the occurrence of future events or circumstances; successful development of Modular Medical's proprietary technologies; whether the market will accept Modular Medical's products and services; anticipated consumer demand for the Company's products; whether Modular Medical can successfully manufacture its products at high volumes; and general economic, industry and political conditions in the United States or internationally; as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
About Modular Medical
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
All trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is David Bosshard and what will he do at Modular Medical (MODD)?
What regulatory status does Modular Medical's Pivot system have as of October 6, 2025 (MODD)?
How does Bosshard's track record support Modular Medical's international plans (MODD)?
What market is Modular Medical targeting with Pivot (MODD)?
Will Bosshard's hire immediately enable sales of Pivot outside the U.S. (MODD)?
